J&J's em­bat­tled In­vokana gets a boost as FDA ex­pands la­bel

For John­son & John­son’s ail­ing di­a­betes drug In­vokana, the ex­pan­sion of its la­bel could be the an­ti­dote that re­vives sales. 

On Mon­day, the FDA ex­pand­ed the drug’s la­bel to slow the pro­gres­sion of di­a­bet­ic nephropa­thy (DKD), as well as to re­duce the risk of hos­pi­tal­iza­tion for heart fail­ure in pa­tients with type II di­a­betes and DKD — an in­di­ca­tion that no oth­er type II di­a­betes med­i­cine is ap­proved for.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.